Back in August 2015, I wrote about an article in the journal Nature on some interesting new discoveries about the role of the hormone progesterone in hormone receptor-positive breast cancer. The research suggested that adding progesterone to standard treatment with tamoxifen or an aromatase inhibitor could increase the effectiveness of treatment for this subtype of breast cancer, while possibly also lowering toxicity. Cancer Research UK reports that these findings are now going to be investigated in three clinical trials that are set to begin. Continue reading A recent article in the journal Nature describes some interesting new discoveries that have been made about the role of the hormone progesterone in hormone receptor-positive breast cancer. The role of progesterone and its receptor in breast cancer has not been well understood. And there has been some controversy about the value of this biomarker in selecting treatment for patients. The study results, if confirmed, could potentially lead to improved treatment options for women with this common sub-type of breast cancer. MLS Last week, I picked up a copy of the local paper. I took a cursory look at it, turning page after page, finding the usual, less than uplifting forecasts about the financial cliff, along side articles about chaos in Egypt, natural disasters, and accidental death. As I turned it over, letting the front page flutter out of my hands, and fall gracelessly, face down on the table top, I glanced down at the back page. The headline, I ran my fingertips over the headline, pausing over the word, “tamoxifen”. I let my index finger dwell on that word for just a moment longer; I inhaled deeply, and read on. The article summarized the important findings of one of the largest breast cancer trials of its kind- aka, “ATLAS” trial, which began in 1996. Tamoxifen is the generic name for the first therapeutic agent that was given to women with hormone positive breast cancer.
Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. Some types of cancer cannot be treated with classical chemotherapy. of Mayo Clinic has found that the drug oxybutynin helps to reduce the frequency and intensity of hot flashes in women who are unable to take hormone replacement therapy, including breast cancer survivors. It blocks the effects of the hormone estrogen in the breast. Scientists from Inserm, CNRS, Sorbonne University, PSL university, University Grenoble Alpes and ESRF, the European Synchrotron, are working on a metallorganic molecule as an antitumor drug. Only around a fifth of women at higher risk of developing breast cancer think they need to take a drug proven to help prevent the disease, according to new research funded by Cancer Research UK and published today (Monday) in Clinical Breast Cancer. Poor diet and lack of exercise are associated with cancer development, but the underlying biology is not well understood. Myotubular myopathy is a severe genetic disease that leads to muscle paralysis from birth and results in death before two years of age. Advanced glycation end products could offer a biological link to help us understand how certain lifestyle behaviors increase cancer risk or lessen the likelihood that an anti-cancer therapy will be effective. Although no treatment currently exists, researchers from the University of Geneva, Switzerland, - working in collaboration with the University of Strasbourg, France, - have identified a molecule that not only greatly reduces the progression of the disease but also boosts life expectancy in animal models by a factor of seven. Facioscapulohumeral muscular dystrophy is the most prevalent dominantly inherited muscular dystrophy in the world. Tamoxifen blocks the actions of estrogen, a female hormone. Certain types of breast cancer require estrogen to grow. Tamoxifen is used to treat some types of breast cancer in men and women. It is also used to lower a woman's chance of developing breast cancer if she has a high risk (such as a family history of breast cancer). Use a barrier form of birth control (such as a condom or diaphragm with spermicide) while you are using this medication and for at least 2 months after your treatment ends. Tamoxifen may also be used for purposes not listed in this medication guide. You should not use tamoxifen if you are allergic to it, or if you have a history of blood clots in your veins or your lungs, or if you are also taking a blood thinner such as warfarin (Coumadin). Before using this medicine, tell your doctor if you have liver disease, high triglycerides (a type of fat in the blood), a history of cataract, or a history of stroke or blood clot. Also tell your doctor if you if you are receiving chemotherapy or radiation treatment.
The research suggested that adding progesterone to standard treatment with tamoxifen or an aromatase inhibitor could increase the. Early trials of continuing adjuvant tamoxifen to 10 years versus stopping tamoxifen at 5 years recruited relatively few patients. Although some of these studies.